Anti-angiogenic properties of novel endostatin fusion proteins through effects on gene expression in human endothelial cells (HUVEC) and solid tumor models.
Esophageal and Stomach Cancer, Colorectal Cancer, Pancreatic and Biliary Cancer, Small bowel Cancer, Benign Hematology, Leukemia, Multiple Myeloma and Related Blood Cancer, Lymphoma, CLL/SLL, Leukemia (Hairy Cell).